
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Science 37 announced a partnership with Xperiome, a global, rare disease health tech company. The partnership furthers Science 37's capabilities to bring research to patients enabling treating physicians the opportunity to advance research as an investigator. Science 37 will leverage Xperiome's insights from Raremark, including a specialized matching engine to connect research-ready members to clinical and real-world study opportunities.
For more information, click






